Myles W. Jackson
- Published in print:
- 2015
- Published Online:
- September 2015
- ISBN:
- 9780262028660
- eISBN:
- 9780262327190
- Item type:
- chapter
- Publisher:
- The MIT Press
- DOI:
- 10.7551/mitpress/9780262028660.003.0002
- Subject:
- History, History of Science, Technology, and Medicine
This chapter explores how the CCR5 gene was patented by several companies both in the United States and in Europe. It discusses how one of the patent holders patented the incorrect sequence and did ...
More
This chapter explores how the CCR5 gene was patented by several companies both in the United States and in Europe. It discusses how one of the patent holders patented the incorrect sequence and did not know the precise function of the gene’s product. The patenting of the gene illustrates how lenient the United States Patent and Trademark Office (USPTO) was in granting gene patents back in the 1990s with a view to encourage growth in the biotechnology sector. It also discusses the views of numerous biomedical researchers on the patenting of the gene by sequencing companies.Less
This chapter explores how the CCR5 gene was patented by several companies both in the United States and in Europe. It discusses how one of the patent holders patented the incorrect sequence and did not know the precise function of the gene’s product. The patenting of the gene illustrates how lenient the United States Patent and Trademark Office (USPTO) was in granting gene patents back in the 1990s with a view to encourage growth in the biotechnology sector. It also discusses the views of numerous biomedical researchers on the patenting of the gene by sequencing companies.
Myles W. Jackson
- Published in print:
- 2015
- Published Online:
- September 2015
- ISBN:
- 9780262028660
- eISBN:
- 9780262327190
- Item type:
- chapter
- Publisher:
- The MIT Press
- DOI:
- 10.7551/mitpress/9780262028660.003.0005
- Subject:
- History, History of Science, Technology, and Medicine
This chapter discusses the patenting of the CCR5 gene in Europe. It compares and contrasts the practices of the United States Patent and Trademark Office (USPTO) with the European Patent Office (EPO) ...
More
This chapter discusses the patenting of the CCR5 gene in Europe. It compares and contrasts the practices of the United States Patent and Trademark Office (USPTO) with the European Patent Office (EPO) with regard to gene patenting. It also focuses on the anatomy of opposing a European patent and offers an informative glimpse into the world of patent litigation. A contrast between the USPTO and the EPO is informative since it points out that there are alternatives: questions of human value are embedded differently in various legal regimes. The situation in which the US finds itself is not inevitable.Less
This chapter discusses the patenting of the CCR5 gene in Europe. It compares and contrasts the practices of the United States Patent and Trademark Office (USPTO) with the European Patent Office (EPO) with regard to gene patenting. It also focuses on the anatomy of opposing a European patent and offers an informative glimpse into the world of patent litigation. A contrast between the USPTO and the EPO is informative since it points out that there are alternatives: questions of human value are embedded differently in various legal regimes. The situation in which the US finds itself is not inevitable.
